Our Partners
Working together – globally
CytoSorbents has forged strategic partnerships with global industry leaders. Below, some of these partnerships are outlined, along with brief descriptions of their respective collaborative endeavors.
CytoSorbents and Fresenius Medical Care have formed a Global Marketing Agreement to address global critical care needs. This collaboration comprises joint marketing efforts and the integration of CytoSorb® into Fresenius Medical Care’s critical-care platforms. Highlights include:
- Enhanced marketing collaboration: Fresenius Medical Care will spearhead worldwide marketing and promotion endeavors for CytoSorb, emphasizing its role as a premier blood purification product for eliminating cytokines, bilirubin, and myoglobin. Over the next three years, diverse marketing channels and campaigns will be utilized to build awareness and foster adoption.
- Expanding the dimension of blood purification of Fresenius Medical Care’s critical care portfolio, CytoSorb offers the capability to eliminate large molecules and toxins beyond the scope of traditional hemodialysis. This integration expands treatment options for critical conditions like sepsis, liver failure, trauma, and lung injury.
- Mutual benefits: Both companies expect sustained growth from this collaboration, leveraging synergies to broaden market outreach and adoption of their combined critical-care solutions. CytoSorbents will subsidize marketing costs via a royalty payment based on CytoSorb sales on Fresenius Medical Care platforms.
- Future innovation: Beyond current marketing endeavors, CytoSorbents and Fresenius Medical Care plan to collaborate on introducing innovative solutions to the market. This includes certifying compatibility between CytoSorb and Fresenius Medical Care’s existing critical-care platforms, facilitating further advances in critical-care treatment.
This partnership constitutes a strategic alliance between CytoSorbents and Fresenius Medical Care to address critical-care challenges, enhance patient care, and drive mutual business growth.
CytoSorbents and Terumo Cardiovascular Group have forged a strategic partnership to introduce CytoSorb to cardiac surgery teams in France, where Terumo holds exclusive distribution rights for the CytoSorb cardiopulmonary bypass (CPB) procedure pack.
This collaboration aims to integrate CytoSorb into cardiac surgery procedures to mitigate dangerous inflammation in highly invasive surgeries such as infective endocarditis, aortic arch reconstruction, and heart and lung transplant. It is also being promoted to remove blood thinners such as ticagrelor and rivaroxaban during cardiac surgery to reduce serious perioperative bleeding.
CytoSorbents and B. Braun Avitum AG have entered into a global co-marketing agreement to promote the use of CytoSorb with B. Braun’s latest OMNI® continuous blood purification platform and OMNIset® Plus blood line set. This partnership aims to provide critically ill patients with greater access to advanced treatment for life-threatening inflammation. CytoSorb, an adsorber used for extracorporeal removal of cytokines and inflammatory mediators, can now be operated with B. Braun’s OMNI® acute dialysis machine.
While B. Braun will supply the market with OMNI® and OMNIset® Plus, CytoSorbents will continue to distribute CytoSorb through its network. Both companies express excitement about the collaboration, highlighting the potential to enhance patient care by combining CytoSorb with B. Braun’s innovative blood purification platform. This agreement applies globally, except for the US market, and specific financial terms were not disclosed.
The collaboration between CytoSorbents and Humedics in the field of liver disease aims to revolutionize diagnostics and treatment. CytoSorbents brings to bear its CytoSorb blood purification technology, which is the only EU-approved extracorporeal liver support therapy capable of removing key liver toxins like bilirubin, and cytokines. On the other hand, Humedics contributes its LiMAx® breath analysis technology, offering rapid and precise assessment of liver function.
The partnership involves a joint product promotion and co-marketing program to increase market awareness, adoption, and sales of both technologies. By leveraging their combined sales teams, the companies aim to generate new customer leads and expand their reach across Europe. Additionally, they plan to collaborate on bringing new innovative solutions to the market, including joint clinical studies and exploration of new therapeutic areas and indications.
Dr. Christian Steiner of CytoSorbents highlights the significant market opportunity for addressing liver diseases with the combined theragnostic approach of CytoSorbents and Humedics. Dr. Ralf Kohnen of Humedics emphasizes the ability of LiMAx to provide real-time quantitative measures of liver function capacity, aiding clinicians in treatment decisions and prognoses. Chris Cramer of CytoSorbents sees this collaboration as a means to rapidly introduce innovative diagnostic and therapeutic offerings to hepatologists and liver support specialists, benefiting millions of patients worldwide suffering from liver disease.